

ACTA DERMATO- VENEREOLOGICA

NEWSLETTER (September 2021)

Editors' Choice in September 2021 in Acta Dermato-Venereologica:

Patient-Reported Outcome Measures in Dermatology: A Systematic Review

Rachael L. Pattinson, Nirohshah Trialonis-Suthakharan, Sunnia Gupta, Alasdair L. Henry, Jacqueline F. Lavallée, Marina Otten, Timothy Pickles, Nick Courtier, Jennifer Austin, Christine Janus, Matthias Augustin, Chris Bundy



Rachel L. Pattinson

Comments by the authors:

Patient-reported outcome or impact measures (PROM/PRIMs) play a key role in clinical decision-making and research (including clinical trials) in dermatology, and consequently influence resource allocation, availability and accessibility of treatments. We conducted the first systematic review of existing PROMs used across dermatological conditions against the gold-standard COSMIN criteria. We found that none of the 36 PROMs identified (including the DLQI and Skindex instruments) met the gold standard criteria. This paper provides an evidence-base for PROM/PRIM choice and provides the rationale for the development of a new PRIM, Patient-Reported Impact of Dermatological Diseases (PRIDD), with patients leading the process. [Read more](#)

Further highlights of September:

Survival of Adjuvant Drugs for Treatment of Pemphigus: A Population-based Cohort Study. [Read more](#)
Khalaf Kridin, Christoph M. Hammers, Ralf J. Ludwig, Dana Tzur Bitan, Arnon D. Cohen

Vitamin D Status in Distinct Types of Ichthyosis: Importance of Genetic Type and Severity of Scaling. [Read more](#)
Mi-Ran Kim, Vinzenz Oji, Frederic Valentin, Heiko Traupe, Jerzy-Roch Nofer, Ingrid Hausser, Hans Christian Hennies, Katja Eckl, Stefan A. Wudy, Alberto Sánchez-Guijo, Laura Kerschke, Judith Fischer, Kira Süßmuth

Chronic Pruritus of Unknown Origin: Clinical Profile and Disease-Related Burden. [Read more](#)
Manuel P. Pereira, Alexandra Farcas, Claudia Zeidler, Sonja Ständer

Dermoscopic Evaluation of Inflammatory Nail Disorders and Their Mimics. [Read more](#)
Sophie Soyeon Lim, Alex Chamberlain, Keunyoung Hur, Jungyoon Ohn, Byeol Han, Victoria Mar, Je-Ho Mun

Prescription Behaviour and Barriers to Prescription of Biologicals for Treatment of Chronic Inflammatory Skin Diseases in Dermatological Practice in Two German Federal States. [Read more](#)
Daniela Weiss, Imke Nordhorn, Linda Tizek, Thomas Werfel, Alexander Zink, Tilo Biedermann, Stephan Traidl, Maximilian C. Schielein

Societal Costs of Moderate-to-severe Atopic Dermatitis Occurring in Adulthood: A Danish Register-based Study. [Read more](#)
Jacob P. Thyssen, Andreas W. Brenneche, Maria E. Madsen, Mikkel H. Pedersen, Dennis J. Trangbaek, Christian Vestergaard

All articles published in September 2021 in Acta Dermato-Venereologica are available [here](#)

Top citations (the most cited paper per publication year 2018–2020):

Year	Title and authors	Citations
2018	Clinical Characteristics of Pruritus and Pain in Patients with Hidradenitis Suppurativa <i>Łukasz Matusiak, Justyna Szczęch, Karolina Kaaz, Edyta Lelonek, Jacek C. Szepietowski</i>	44
2019	European S2k Guideline on Chronic Pruritus <i>Elke Weisshaar, Jacek C. Szepietowski, Florence J. Dalgard, Simone Garcovich, Uwe Gieler, Ana M. Giménez-Arnau, Julien Lambert, Tabi Leslie, Thomas Mettang, Laurent Misery, Ekin Şavk, Markus Streit, Erwin Tschachler, Erwin Tschachler, Joanna Wallengren, Sonja Ständer</i>	52
2020	Cutaneous Clinico-Pathological Findings in Three COVID-19-Positive Patients Observed in the Metropolitan Area of Milan, Italy <i>Raffaele Gianotti, Stefano Veraldi, Sebastiano Recalcati, Marco Cusini, Massimo Ghislanzoni, Francesca Boggio, Lindy P. Fox</i>	62

ActaDV on a new publication platform

We are excited to announce that Acta Dermato-Venereologica (ActaDV) has just transitioned publication system from our own internally developed system to a publicly supported system called Open Journal Systems (OJS).

The new publication platform affords ActaDV the opportunity to improve the quality and speed of our publication process as well as expand the reach of its published contents. Advantages that this change in system can offer ActaDV and its stakeholders include:

- Modernization and conformation to industry standards – OJS was designed specifically for open access, peer-reviewed publishing and supports for example JATS XML standardization, which has become the standard ‘model’ for journal articles. JATS XML is used in most scholarly communities today (including public archives like PubMed Central amongst other indexes and hosts).
- Increased reach of journal contents – by offering a platform that is optimized for content discovery across search engines such as Google, Google Scholar, and Bing, and that provides comprehensive indexing. In short, contents on the new platform will be machine-readable and searchable meaning they can more easily be accessed, read and indexed.
- Increased efficiency and transparency in the publication process - saving time and energy for both authors and the editorial team while maintaining integrity throughout the editorial process. By getting an end-to-end journal publishing and management system, all steps of the publication can be handled in the same system and a lot of what used to be manual work will now be automated. Hence the new system not only provides the technical infrastructure for the presentation of contents, but also the complete editorial-management workflow (including submission, peer-review, and indexing).
- Increased quality and security – by streamlining the record-keeping process, ActaDV can now offer an even more secure environment for archiving and stewardship of scholarly content.
- Continuous development – with more than 10,000 journals worldwide OJS is continuously being developed with new features being added as scholarly communication is developed.
- Improved user experience – many ActaDV authors already have an account with OJS and are familiar with the submission process.

Changes in the Editorial Board of ActaDV

We would like to welcome 2 new Section Editors to *ActaDV*: *Sam Polesie* in the area of *Machine learning and artificial intelligence* and *Stefano Piaserico* in the area of *Psoriasis, nonmelanoma skin cancer, cutaneous manifestation in immunosuppressed patients*. A brief presentation of their background, and the knowledge they bring to *ActaDV* follows.



Sam Polesie is a specialist physician working at the Department of Dermatology and Venereology at Sahlgrenska University Hospital in Sweden. His PhD project focused on whether methotrexate (MTX) increased the risk of melanoma Overall or if MTX had only a minimal effect on the risk of developing melanoma. These studies have contributed to an increased understanding of the risk benefit assessment of MTX, especially for patients with a history of melanoma disease. Since 2018, *Sam Polesie* has conducted research in machine learning (ML). The work began with examining the attitudes towards artificial intelligence (AI) among dermatologists and dermatopathologists. Overall, attitudes towards AI were positive and both dermatologists and dermatopathologists saw great potential with an increased use of ML. *Sam Polesie's* ML-related research has thereafter continued by developing applications in imaging that can prove valuable for healthcare. *Sam Polesie* also conducts research on dermatoscopic findings that may distinguish between *in situ* and invasive melanomas. Furthermore, during dermatology residency, he worked a year at the departments of clinical genetics and clinical pathology, where he gained an interest in genetic diseases that affect the skin (genodermatoses). Thus since 2021 he is engaged in a research group led by Dr Sirkku Peltonen, which will, among other things, investigate epidemiological aspects of genodermatosis in Sweden.



Stefano Piaserico took his degree in Medicine in 1997 at the University of Padova, graduating summa cum laude, with a thesis entitled: "Skin cancer in Organ Transplant Recipients". He took his Ph.D. in Biochemistry and Biophysics in 2006 from the University of Padua, with a thesis entitled "Photodynamic therapy in dermatology: State of the art and new perspectives". *Stefano Piaserico's* research is mainly based on psoriasis, psoriatic arthritis, organ transplant recipients, photodynamic therapy and skin cancer. In particular, he is focused on comorbidities of psoriasis. He recently unraveled the complex association between psoriasis-related inflammation and microvascular dysfunction within the myocardial tissue. *Stefano Piaserico* has built up a wide portfolio of more than 160 publications in several scientific journals, including Journal of the American Academy of Dermatology, Circulation, Transplantation, British Journal of Dermatology, Acta Dermato-Venerologica, European Journal of Dermatology and Journal of the European Academy of Dermatology and Venereology. He has knowledge of the FDA and EMEA regulations related to Good Clinical Practice and Clinical Trial, and has participated in more than 15 clinical trials to date, mostly as a Principal Investigator. *Stefano Piaserico* has been responsible for several Investigator's Initiated clinical trials, some of which were supported by International Pharmaceutical Companies. He is also an associate of numerous professional organisations including the Italian Society of Dermatology and the European Academy of Dermatology and Venereology (EADV). Chair, Italian Society of Dermatology, Regional Responsible, 2017 to present.